Working... Menu

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00458601
Recruitment Status : Completed
First Posted : April 11, 2007
Last Update Posted : January 16, 2018
Information provided by (Responsible Party):
Celldex Therapeutics

Brief Summary:
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.

Condition or disease Intervention/treatment Phase
Malignant Glioma Drug: CDX-110 with GM-CSF Drug: Temozolomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Study Start Date : August 2007
Actual Primary Completion Date : November 2010
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CDX-110 with GM-CSF Drug: CDX-110 with GM-CSF
Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
Other Name: CDX-110 with sargramostim (GM-CSF) (Leukine®)

Drug: Temozolomide
Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
Other Name: Temodar

Primary Outcome Measures :
  1. Progression-free survival status [ Time Frame: 5.5mo ]

Secondary Outcome Measures :
  1. Safety and tolerability characterized by adverse events (term, grade, frequency). [ Time Frame: 2 years ]
  2. Safety and tolerability characterized by physical examinations. [ Time Frame: 2 years ]
  3. Safety and tolerability characterized by hematologic and metabolic panel (including CBC with differential, electrolytes, BUN, Cr, liver associated enzymes). [ Time Frame: 2 years ]
  4. Safety and tolerability characterized by urinalysis. [ Time Frame: 2 years ]
  5. Safety and tolerability characterized by vital signs. [ Time Frame: 2 years ]
  6. Immune response; T-cell response to vaccine. [ Time Frame: 2 years ]
  7. Immune response; antibody response to vaccine. [ Time Frame: 2 years ]
  8. Immune response; HLA typing. [ Time Frame: 2 years ]
  9. Overall survival. [ Time Frame: indeterminate ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.
  • Gross total resection followed by conventional chemoradiation therapy without progression of disease.

Exclusion Criteria:

  • Presence of diffuse leptomeningeal disease or gliomatosis cerebri.
  • Systemic corticosteroid therapy > 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.
  • Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.
  • Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00458601

  Show 34 Study Locations
Sponsors and Collaborators
Celldex Therapeutics

Publications of Results:
Layout table for additonal information
Responsible Party: Celldex Therapeutics Identifier: NCT00458601     History of Changes
Other Study ID Numbers: CDX110-003
First Posted: April 11, 2007    Key Record Dates
Last Update Posted: January 16, 2018
Last Verified: August 2016

Keywords provided by Celldex Therapeutics:
EGFRvIII vaccinetemozolomidecancer vaccineimmunotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological